Market Place
Sourcing Support
FDA says no to Astellas` geographic atrophy drug
19 Nov 2024 //
PHARMAPHORUM
Astellas cruises into first DTC campaign for GA med Izervay
30 Sep 2024 //
FIERCE PHARMA
Aviceda Completes Phase 2b SIGLEC Study Enrollment for AVD-104
24 Sep 2024 //
BUSINESSWIRE
Astellas touts 2-year trial results for GA drug Izervay
06 Nov 2023 //
FIERCE PHARMA
Apellis counters Izervay results with long-term data of its own
06 Nov 2023 //
FIERCE PHARMA
IZERVAY Monthly or Every Month Reduced Geographic Atrophy Lesion Growth
04 Nov 2023 //
PR NEWSWIRE
Astellas touts 2-year trial of Izervay, but questions remain
19 Sep 2023 //
FIERCE PHARMA
Iveric Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY
18 Sep 2023 //
PR NEWSWIRE
EMA Accepts Iveric`s Marketing Authorization Application for Avacincaptad Pegol
17 Aug 2023 //
PR NEWSWIRE
Iveric Receives FDA Approval for IZERVAY, a New Treatment for Geographic Atrophy
05 Aug 2023 //
PR NEWSWIRE
CARVYKTI Receives Approval from Japan’s Ministry of Health
27 Sep 2022 //
BUSINESSWIRE
Iveric Bio reports positive PhIII readout as shares surge, FDA filing planned
07 Sep 2022 //
ENDPTS
Iveric Bio Announces Positive Data from Zimura GATHER2 PIII Trial
06 Sep 2022 //
PRESS RELEASE
Iveric Bio Announces New Post-Hoc Analyses of Zimura from GATHER1 Trial
07 Feb 2022 //
BUSINESSWIRE
IVERIC bio Announces results of GATHER1 Phase 3 Clinical Trial for Zimura®
01 Sep 2020 //
BIOSPACE
IVERIC bio Announces First Patient Dosed in Second Zimura®
29 Jun 2020 //
BUSINESSWIRE
IVERIC bio to Announce Zimura® 18 Month Data from the OPH2003 Ph3 Clinical Trial
14 Jun 2020 //
BUSINESSWIRE
IVERIC bio Announces Fast Track Designation from FDA for Zimura®
03 Apr 2020 //
BUSINESSWIRE
IVERIC bio Announces Design for Second Pivotal Clinical Trial of Zimura®
13 Jan 2020 //
BUSINESSWIRE
IVERIC bio Initiating Second Pivotal Clinical Trial of Zimura®
12 Nov 2019 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.